NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS Stock Report

Market Cap: US$4.1b

NewAmsterdam Pharma Future Growth

Future criteria checks 5/6

NewAmsterdam Pharma is forecast to grow earnings and revenue by 65.3% and 54.3% per annum respectively. EPS is expected to grow by 63.1% per annum. Return on equity is forecast to be -15.6% in 3 years.

Key information

65.3%

Earnings growth rate

63.06%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate54.3%
Future return on equity-15.59%
Analyst coverage

Good

Last updated30 Jun 2026

Recent future growth updates

Analysis Article • May 13

Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report

NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) shareholders are probably feeling a little disappointed, since its...
Analysis Article • Mar 03

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

The annual results for NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) were released last week, making it a good time...

Recent updates

Analysis Article • May 13

Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts

Celebrations may be in order for NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) shareholders, with the analysts...
Seeking Alpha • Apr 16

NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today

Summary NewAmsterdam Pharma is advancing obicetrapib, an oral CETP inhibitor, targeting unmet LDL-C lowering needs in cardiovascular disease patients. Obicetrapib met primary and secondary endpoints in three Phase 3 trials, with significant LDL-C reductions and favorable safety, supporting regulatory filings in Europe and the US. NAMS anticipates regulatory decisions in Europe in H2 2026, with US NDA likely post-PREVAIL CVOT data; commercial preparations and partnerships are underway. With $729m cash and multiple ongoing studies, NAMS faces single-asset risk but holds significant upside from potential multi-indication approvals and European royalty streams. Read the full article on Seeking Alpha
Analysis Article • Dec 24

We're Hopeful That NewAmsterdam Pharma (NASDAQ:NAMS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 18

Rainbows and Unicorns: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Became A Lot More Optimistic

NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) shareholders will have a reason to smile today, with the analysts...
Analysis Article • Jun 10

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14%

The analysts covering NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) delivered a dose of negativity to shareholders...
Analysis Article • May 29

Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation

Key Insights NewAmsterdam Pharma's Annual General Meeting to take place on 4th of June Total pay for CEO Michael...
Analysis Article • May 13

Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report

NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) shareholders are probably feeling a little disappointed, since its...
Seeking Alpha • Mar 01

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Summary New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to file for European approval in 2025, with ongoing trials potentially confirming additional cardiovascular benefits. Despite competition, obicetrapib's oral administration and lack of side effects position it favorably against injectable PCSK9 inhibitors. Valuation models suggest significant upside potential, with market capitalization possibly reaching $6.78 billion to $21.69 billion upon successful commercialization. Read the full article on Seeking Alpha
Analysis Article • Feb 27

Companies Like NewAmsterdam Pharma (NASDAQ:NAMS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 04

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Summary NewAmsterdam Pharma's Obicetrapib, a CETP inhibitor, shows promise in reducing LDL-C, addressing unmet cardiovascular needs, and has favorable Phase 3 trial results. Obicetrapib's potential regulatory filing by 2025 and its competitive edge over similar drugs position NAMS for significant market share in cardiovascular therapies. This drug significantly reduced LDL-C in Phase 3 trials, outperforming similar therapies. It also seems highly effective at lowering Lp(a). NAMS has a strong cash position, no debt, and a promising pipeline, making it a compelling investment despite inherent biotech risks. Read the full article on Seeking Alpha
Analysis Article • Oct 01

Will NewAmsterdam Pharma (NASDAQ:NAMS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 03

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

The annual results for NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) were released last week, making it a good time...

Earnings and Revenue Growth Forecasts

NasdaqGM:NAMS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283663-149-25412
12/31/2027151-198-187-23814
12/31/202627-224-159-16315
3/31/202623-213-142-142N/A
12/31/202523-204-148-148N/A
9/30/202535-221-145-144N/A
6/30/202564-166-124-124N/A
3/31/202547-187-141-140N/A
12/31/202446-242-159-159N/A
9/30/202434-199-155-154N/A
6/30/20247-229-189-189N/A
3/31/20247-229-164-164N/A
12/31/202314-177-141-141N/A
9/30/202319-165-81-81N/A
6/30/202311-162-2-2N/A
3/31/202361-9433N/A
12/31/2022103-231011N/A
9/30/202297-8-30-29N/A
6/30/20229837-64-64N/A
3/31/2022524-48-48N/A
12/31/2021N/A-42-30-30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NAMS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: NAMS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NAMS is expected to become profitable in the next 3 years.

Revenue vs Market: NAMS's revenue (54.3% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: NAMS's revenue (54.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NAMS is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 23:57
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NewAmsterdam Pharma Company N.V. is covered by 19 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Steven SeedhouseCantor Fitzgerald & Co.
Geoffrey MeachamCitigroup Inc
Asad HaiderGoldman Sachs